Daily Ards Research Analysis
Analyzed 7 papers and selected 3 impactful papers.
Summary
A meta-analysis of randomized trials in ARDS shows that open-lung strategies with recruitment maneuvers and high PEEP do not reduce hospital mortality when lung recruitability is not assessed, emphasizing phenotype-guided ventilation. A pilot study of a continuous-flow ventilator (VENTIJET) in moderate ARDS demonstrates safety and feasibility with stable gas exchange. Beyond ARDS, a neonatal case-control study confirms gestational age as the dominant predictor of severe ROP and suggests LMR as an adjunct biomarker.
Research Themes
- Personalized ventilation in ARDS
- Novel ventilatory technologies
- Risk stratification in neonatal care
Selected Articles
1. Open lung ventilation with low tidal volumes, staircase recruitment maneuvers, high PEEP and decremental PEEP titration vs ARDSNet in ARDS: A systematic review and meta-analysis.
Across 7 RCTs (n=1545), open-lung ventilation using low VT, SRMs, high PEEP, and decremental PEEP titration did not reduce hospital mortality versus ARDSNet in ARDS patients without prior recruitability assessment. These results argue against routine, unselected application of aggressive recruitment/high PEEP and support phenotype-guided ventilation.
Impact: It synthesizes randomized evidence to deliver a clear negative finding on a widely used strategy, steering the field toward recruitability-informed, individualized ventilation.
Clinical Implications: Avoid routine use of aggressive recruitment and high PEEP without assessing lung recruitability; prioritize individualized PEEP titration and consideration of recruitability testing when applying open-lung concepts.
Key Findings
- Across 7 RCTs (n=1545), OLV did not reduce hospital mortality compared with ARDSNet (RR 1.03, 95% CI 0.94–1.13).
- The analysis specifically addressed ARDS populations without prior assessment of lung recruitability.
- The OLV interventions combined low tidal volumes, staircase recruitment maneuvers, high PEEP, and decremental PEEP titration.
Methodological Strengths
- Systematic search across PubMed, Scopus, Web of Science, Embase, and Cochrane
- Restriction to randomized controlled trials with standard effect estimates (RR, WMD, 95% CI)
Limitations
- Lack of stratification by lung recruitability limits applicability to recruitable phenotypes
- Potential heterogeneity in OLV protocols (SRMs, PEEP targets, titration methods) across trials
Future Directions: Conduct RCTs that predefine and stratify by lung recruitability and test individualized PEEP strategies; evaluate patient-centered outcomes and harms of SRMs/high PEEP.
The impact of open lung ventilation (OLV) with low tidal volumes (TV), staircase recruitment maneuvers (SRMs), high positive end-expiratory pressure (PEEP), and decremental PEEP titration on acute respiratory distress syndrome (ARDS) patients is still uncertain. We aim to assess the impact of this OLV versus ARDS Network (ARDSNet) on patients with ARDS. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). PubMed, Scopus, Web of Science, Embase, and Cochrane were searched from inception through August 11, 2025. Statistical analysis used risk ratios (RR), weighted mean differences (WMD), and 95 % confidence intervals (95 % CI). Based on seven RCTs involving 1545 participants, it was found that for ARDS patients whose lung recruitability has not been assessed, compared to ARDSNet, OLV does not reduce hospital mortality (RR: 1.03; 95 % CI: 0.94 to 1.13;
2. Continuous-flow ventilation with VENTIJET in moderate ARDS: a pilot safety and feasibility study.
In 14 intubated adults with moderate ARDS, continuous-flow ventilation via VENTIJET was feasible and safe over 24 hours, with no device-related serious adverse events. Oxygenation and compliance showed modest, non-significant short-term improvements while CO2 elimination and hemodynamics remained stable, supporting further controlled trials.
Impact: Introduces and clinically tests a novel continuous-flow ventilator platform that may reduce cyclic strain, establishing first-in-patient feasibility and safety signals.
Clinical Implications: Not practice-changing yet; centers should consider enrolling patients in trials to evaluate CFV against conventional ventilation across ARDS severities and assess impacts on ventilator-induced lung injury.
Key Findings
- VENTIJET CFV was feasible and safe in all 14 participants, with no device-related serious adverse events.
- After 1 hour, PaO2/FiO2 was 200 mm Hg versus 192 mm Hg at baseline (p=0.090), indicating non-significant short-term oxygenation change.
- Over 24 hours, modest improvements in oxygenation and respiratory system compliance occurred with stable CO2 elimination, transpulmonary pressures, and hemodynamics.
Methodological Strengths
- Prospective, protocolized pilot with predefined safety and feasibility endpoints
- Registered clinical trial (NCT07121257)
Limitations
- Small, single-center, nonrandomized single-arm design limits generalizability
- Short 24-hour exposure window precludes assessment of clinical outcomes
Future Directions: Conduct multicenter randomized controlled trials comparing CFV with conventional ventilation across ARDS severities, including biomarkers of ventilator-induced lung injury and patient-centered outcomes.
BACKGROUND: Acute respiratory distress syndrome (ARDS) remains associated with high mortality and ventilator-induced lung injury. Continuous-flow ventilation (CFV) may reduce cyclic strain, but faced technical limitations. VENTIJET is a novel nozzle-based CFV ventilator designed for safe use in critically ill adults. This pilot study evaluated its feasibility and safety in patients with moderate ARDS. METHODS: We conducted a prospective, single-center pilot safety and feasibility study in intubated adults with moderate ARDS and stable oxygenation. After a 1-h baseline period with volume-controlled ventilation (Puritan Bennett™ 840), patients received up to 24 h of VENTIJET ventilation, then returned to conventional ventilation. Primary endpoints were feasibility and safety; secondary exploratory endpoints included gas exchange and respiratory mechanics. RESULTS: Fourteen patients were enrolled. VENTIJET ventilation was successfully delivered in all participants without protocol interruptions or device-related serious adverse events. After 1 h, PaO₂/FiO₂ was 200 mm Hg compared to 192 mm Hg at baseline (p = 0.090). Over 24 h, oxygenation and respiratory system compliance showed modest improvement, with stable carbon dioxide (CO₂) elimination, transpulmonary pressures, and hemodynamics. CONCLUSIONS: In patients with moderate ARDS, VENTIJET CFV was feasible and safe, maintaining stable gas exchange with modest improvements in respiratory mechanics. These findings support further evaluation in larger, controlled trials, including the full spectrum of ARDS. Trial registration ClinicalTrials.gov Identifier NCT07121257.
3. Risk factors for severe retinopathy of prematurity: A retrospective case-control study.
In a single-center retrospective case-control study of 80 preterm infants, gestational age was the only independent risk factor for severe ROP, while complications (BPD, RDS, sepsis, transfusions) were associated on univariate analysis. GA ≤30.5 weeks predicted severe ROP with 76.2% sensitivity and 71.1% specificity; LMR was lower in severe ROP at birth and 1 week.
Impact: Clarifies that gestational age dominates risk while highlighting LMR as a plausible inflammatory biomarker for early risk stratification.
Clinical Implications: Prioritize intensive screening and early ophthalmology referral for infants ≤30.5 weeks GA; consider LMR as an adjunct risk indicator; maternal late-pregnancy lipids are unlikely to inform ROP risk.
Key Findings
- Gestational age was the sole independent risk factor for severe ROP (P<0.001).
- GA ≤30.5 weeks predicted severe ROP with 76.2% sensitivity and 71.1% specificity (P<0.001).
- LMR was significantly lower in severe ROP within 24 hours of birth (P=0.015) and at 1 week (P=0.01).
- Perinatal complications (BPD, RDS, sepsis, transfusion) were associated with severe ROP in univariate analyses.
- Maternal third-trimester lipid parameters showed no significant association with severe ROP.
Methodological Strengths
- Clear case-control design with multivariable logistic regression
- ROC analysis provided clinically interpretable thresholds for GA
Limitations
- Single-center retrospective design with modest sample size (n=80) limits generalizability
- Residual confounding cannot be excluded; external validation is needed
Future Directions: Validate LMR and GA-based thresholds in multicenter prospective cohorts and integrate inflammatory biomarkers into risk prediction models.
The present study aimed to investigate the risk factors associated with severe retinopathy of prematurity (ROP) in preterm infants and to identify predictive biomarkers for early risk stratification. The present retrospective case-control study analyzed preterm infants who underwent ROP screening at Hebei General Hospital (Shijiazhuang, China) between September 2018 and July 2023. Participants were stratified into mild (n=42) and severe ROP (n=38) groups based on fundus examination results and treatment requirements. Demographic characteristics, perinatal complications, maternal third-trimester lipid profiles and serial hematological parameters (within 24 h of birth and at 1 week of age) were analyzed. Binary logistic regression analysis was performed to identify independent risk factors, and receiver operating characteristic (ROC) curves were constructed to evaluate predictive performance. Significant differences were observed between severe and mild ROP groups in gestational age, birth weight and 1-min Apgar score (all P<0.001). Perinatal complications significantly associated with severe ROP included neonatal bronchopulmonary dysplasia (P<0.001), neonatal respiratory distress syndrome (P=0.003), neonatal sepsis (P=0.009) and blood transfusion requirements (P<0.001). Among hematological parameters, lymphocyte-to-monocyte ratio (LMR) was significantly lower in the severe ROP group both within 24 h of birth (P=0.015) and at 1 week of age (P=0.01). Multivariate logistic regression identified gestational age as the sole independent risk factor for severe ROP (P<0.001). ROC curve analysis revealed that gestational age ≤30.5 weeks predicted severe ROP with 76.2% sensitivity and 71.1% specificity (P<0.001). Maternal third-trimester lipid parameters showed no significant associations with severe ROP development. In conclusion, gestational age represents the most significant independent predictor of severe ROP in preterm infants, with infants born at ≤30.5 weeks showing significantly increased risk. Additional risk factors include major perinatal complications and altered inflammatory profiles characterized by reduced LMR. These findings support enhanced surveillance protocols for preterm infants and suggest the potential utility of inflammatory biomarkers in ROP risk stratification strategies.